Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors”

3 trials

Showing 3 of 3 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02079740
What this trial is testing

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI) 96
Early research (Phase 1)Study completedNCT04742556
What this trial is testing

Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Who this might be right for
Solid Tumors, KRAS Mutation
Boehringer Ingelheim 15
Early research (Phase 1)Study completedNCT05187858
What this trial is testing

LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Who this might be right for
NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Lupin Ltd. 15

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation